Dr. Sherrif F. Ibrahim, MD
Mohs Surgery (MOHS-Micrographic Surgery Physician)
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 255
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
NY license 242171 -
Dermatology Physician
NY license 242171
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Rochester Dermatologic Surgery PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 255
- Services billed
- 2,022
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 5,400 | 25 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 275 | 228 |
| New patient office or other outpatient visit, 30-44 minutes | 156 | 156 |
| Destruction of precancer skin growth, 2-14 growths | 149 | 21 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 101 | 91 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 88 | 85 |
| Established patient office or other outpatient visit, 20-29 minutes | 83 | 82 |
| Removal and microscopic exam of growth, each additional block after 5 tissue blocks | 49 | 28 |
| Destruction of precancer skin growth, 1 growth | 45 | 33 |
| Established patient office or other outpatient visit, 10-19 minutes | 40 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluorouracil Other prescribers in Victor, NY | 22 |
| Doxycycline Monohydrate Other prescribers in Victor, NY | 21 |
| Mupirocin Other prescribers in Victor, NY | 18 |
| Cefadroxil Other prescribers in Victor, NY | 14 |
| Clobetasol Propionate Other prescribers in Victor, NY | 13 |
| Erivedge (vismodegib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 38 payments worth $73,988 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $35,622 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $22,689 |
| Galderma Laboratories, L.P. | $13,626 |
| Sun Pharmaceutical Industries Inc. | $2,000 |
| Novartis Pharmaceuticals Corporation | $29.07 |
| AbbVie Inc. | $22.96 |
| Consulting Fee | $37,320 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $34,113 |
| Travel and Lodging | $1,699 |
| Food and Beverage | $858 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $5,978 |
| Regeneron Healthcare Solutions, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,124 |
| Regeneron Healthcare Solutions, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,124 |
| Galderma Laboratories, L.P. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Galderma Laboratories, L.P. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Galderma Laboratories, L.P. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $3,416 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,124 |
| Regeneron Healthcare Solutions, Inc. Nov 26, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to AMHERST, NY · in-kind | $785 |
| Regeneron Healthcare Solutions, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,124 |
| Galderma Laboratories, L.P. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Healthcare Solutions, Inc. Oct 29, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to FARMINGTON HILLS, MI · in-kind | $517 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,053 |
| Regeneron Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $1,721 |
| Regeneron Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $1,147 |
| Regeneron Healthcare Solutions, Inc. Sep 3, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to FARMINGTON HILLS, MI · in-kind | $397 |
| Galderma Laboratories, L.P. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $6,832 |
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $3,416 |
| Regeneron Healthcare Solutions, Inc. May 23, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,708 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $3,416 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,562 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $854 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $5,978 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $1,708 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $854 |
| Galderma Laboratories, L.P. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,500 |
| Sun Pharmaceutical Industries Inc. Mar 3, 2025 | Consulting Fee Odomzo · Oncology | $2,000 |
| Regeneron Healthcare Solutions, Inc. Jan 8, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $771 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $365,417 in research payments for these studies, mostly to the institutions running them.
- Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Completed · NCT03889912 - Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06585410 - [Trial of device that is not approved or cleared by the U.S. FDA]
Galderma Laboratories, L.P. · Withheld · NCT05461300 - Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc. · Completed · NCT05662202 - Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Biofrontera Inc. · Active, not recruiting · NCT03573401 - A non-ranodmized, open-label, multicenter study to evaluate the safety and tolerability of BF-200 ala (ameluz) and bf-rhodoled xl in the expanded field-directed treatment of actinic keratosis on the face and scalp wit…
Biofrontera Inc. - Activation of ameluz with bbl heroic for the treatment of actinic keratoses and photodamage
Biofrontera Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.